Skip to main content

Table 1 Characteristics of study patients at ICU admission

From: De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety

Characteristics

De-escalation

p

Yes (n = 38)

No (n = 152)

Age, years

63 [56–68]

63 [55–72]

0.57

Female gender n (%)

8 (21)

55 (36)

0.067

SAPS II

49 [30–68]

54 [36–71]

0.38

Comorbidities n (%)

 Diabetes

8 (21)

30 (20)

0.87

 COPD

9 (24)

33 (22)

0.79

 Chronic heart failure

8 (21)

30 (20)

0.87

 Cirrhosis

4 (11)

10 (6)

0.49

 Chronic dialysis

9 (24)

14 (9)

0.014*

Immunosuppression n (%)

 Chemotherapy

7 (18)

13 (9)

0.076

 Corticosteroid therapy

9 (24)

29 (19)

0.53

Transfer from

  

0.66

 Home

4 (11)

21 (14)

 

 Other wards

25 (66)

104 (68)

 

 Other ICUs

9 (24)

27 (18)

 

Admission category

  

0.75

 Medical

22 (58)

98 (64)

 

 Surgical

15 (39)

51 (34)

 

 Other (trauma, burn)

1 (3)

3 (2)

 

Cause for ICU admission

 Acute exacerbation of COPD

3 (8)

26 (17)

0.16

 Acute respiratory distress syndrome

12 (32)

41 (27)

0.57

 Community-acquired pneumonia

11 (29)

32 (21)

0.30

 Hospital-acquired pneumonia

6 (16)

38 (25)

0.23

 Congestive heart failure

0 (0)

7 (5)

0.18

 Neurologic failure

0 (0)

7 (5)

0.18

 Poisoning

1 (3)

15 (10)

0.15

 Septic shock

22 (58)

89 (59)

0.94

Infection at ICU admission

37 (97)

135 (89)

0.17

Prior antibiotic treatment

16 (42)

69 (45)

0.72

Prior antifungal treatment

5 (13)

15 (10)

0.56

  1. Data are N (%), or median (interquartile range)
  2. COPD chronic obstructive pulmonary disease, ICU intensive care unit, SAPS simplified acute physiology score
  3. * Odds ratio (95% confidence interval) 3.1 (1.21–7.74)